Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review
Frontiers in Pharmacology · 29.06.2026 · 17
DOI: 10.3389/fphar.2026.1812662 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Covadonga Canga-Espina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Clinical Psychology, Clínica Universidad de Navarra, Pamplona, Spain. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to personalize pharmacotherapy. Dose adjustment of sertraline is currently based on clinical judgment. Preliminary evidence shows relationships between sertraline blood concentration and clinical outcomes. This review aims to evaluate the clinical utility of TDM of sertraline.
Methods
A comprehensive, systematic search of studies in several databases was conducted up to 2025/06/26 on the potential relationship between TDM of sertraline and measures of efficacy, safety and tolerability. The search identified 5 clinical trials and 5 observational studies (N = 1106).
Results
The included studies are highly heterogeneous. Most of the results are observational, mainly focused on depression and obsessive-compulsive disorder, covering the whole dosage range, with populations representing the whole life-span, observational periods from 4 weeks to 1 year. Efficacy assessments utilized diverse scales and heterogeneous measures of safety/tolerability. Most of the studies do not detect concentration-effect relationships. Preliminary, non-linear concentration-effect relationships are reported for efficacy and tolerability.
Conclusion
There is no sufficient evidence for the clinical utility of a generalized use of TDM for sertraline. Preliminary evidence suggests associations between blood concentrations of sertraline and clinical outcomes, potentially supporting the utility of its TDM as guide for clinical judgement in the treatment of depression and obsessive-compulsive disorder, particularly in populations with specific risks. Further studies using symptom-specific clinical scales are needed to assess the potential clinical utility of sertraline TDM in personalized medicine. Systematic Review Registration https://osf.io/84trm/overview .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Clinical Psychology, Clínica Universidad de Navarra, Pamplona, Spain.
- Pharmacy Services, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
- Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland.
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Zitieren
APA
Canga-Espina, C., Bullard, J. P., Tapia-Alzuguren, B., Gędek, A., Aubá, E., Ortuño, F., Aldaz-Pastor, A., & Molero, P. (2026). Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1812662
Vancouver
Canga-Espina C, Bullard JP, Tapia-Alzuguren B, Gędek A, Aubá E, Ortuño F, et al. Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1812662
BibTeX
@article{CangaEspina2026,
author = {Canga-Espina, Covadonga and Bullard, José Pablo and Tapia-Alzuguren, Begoña and Gędek, Adam and Aubá, Enrique and Ortuño, Felipe and Aldaz-Pastor, Azucena and Molero, Patricio},
title = {Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1812662}
}
EUVIMED